港股異動丨維亞生物(1873.HK)大漲逾9% 與百圖生科達成戰略合作 推動創新藥物研發
格隆匯5月17日丨維亞生物(1873.HK)午後漲幅擴大至9.23%,報7.1港元,成交額放大至8145萬港元,總市值137億港元。維亞生物日前公佈,與百圖生科簽署戰略合作協議,將基於百圖生科的AI+生物計算引擎,與公司基於結構的綜合性新藥發現平台形成技術互補,共同加速推進生物創新藥物研發設計。百圖生科由百度創始人李彥宏發起創立,致力通過先進AI技術及前沿生物技術的融合創新,加速新型藥物和診斷產品的研發。光大證券此前表示,公司的EFS業務進入收穫期,確定性和穩定性逐漸增強,維持“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.